1 of 1
Story summary
- U.S. President Donald Trump struck deals with 26 pharmaceutical companies to lower U.S. prescription drug prices.
- He announced that all 50 states will adopt the policy, matching prices paid by reference nations.
- Experts warned the most-favoured-nation (MFN) pricing could raise Canadian drug costs or delay new medicine launches.
- Public Citizen released redacted agreements showing Eli Lilly’s GLP-1 drugs excluded from the MFN pricing.